NCT05768529 is a Phase 1, PHASE2 clinical trial of U16 in Relapsed or Refractory Non-Hodgkin's Lymphoma, sponsored by Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd.

Who is sponsoring NCT05768529?

NCT05768529 is sponsored by Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd.

What drugs are being tested in NCT05768529?

Interventions in NCT05768529: U16.

What condition does NCT05768529 study?

NCT05768529 studies Relapsed or Refractory Non-Hodgkin's Lymphoma.

Is NCT05768529 still recruiting?

NCT05768529 is currently recruiting now. Last updated 21 September 2023.

Last reviewed 2023-09-21 · How we verify

NCT05768529

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Recruiting now Phase 1, PHASE2 Last updated 21 September 2023

What this trial tests

Phase 1, PHASE2 trial testing U16 in Relapsed or Refractory Non-Hodgkin's Lymphoma in 100 participants. Currently enrolling.

Timeline

28 March 2023

Primary endpoint
31 December 2024

31 December 2026

Quick facts

Lead sponsor	Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase	Phase 1, PHASE2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	28 March 2023
Primary completion	31 December 2024
Estimated completion	31 December 2026
Sites	2 locations across China

Drugs / interventions tested

U16 — full drug profile →

Conditions studied

Relapsed or Refractory Non-Hodgkin's Lymphoma — all drugs for Relapsed or Refractory Non-Hodgkin's Lymphoma →

Sponsor

Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd — full company profile →

Who can join

Adults 18 to 70, any sex, with Relapsed or Refractory Non-Hodgkin's Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is a Phase I/II, single-arm, open-label clinical trial, and its primary objective of phase I and phase II is to evaluate the safety and efficacy of U16 Injection in the treatment of relapsed or refractory NHL,respectively.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd trials

Trials by the same sponsor.

NCT07036250 — Clinical Study of U32 in Patients With Acute Myeloid Leukemia · Phase 1, PHASE2 · recruiting
NCT07453446 — Clinical Study of U29 Injection (CD30-CART) in Patients With CD30-Positive Relapsed/Refractory Lymphoma · Phase 1 · recruiting
NCT07093073 — Clinical Study of U01（ssCART-19） in Patients With B-Cell Lymphoma · Phase 1 · recruiting
NCT07093086 — Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell Lymphoma · Phase 1 · recruiting
NCT06614686 — U87 CAR-T in Patients With Advanced Head and Neck Tumors · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05768529 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Last refreshed: 21 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05768529.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing